Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Programming CAR-T cells to kill cancer.

Labanieh L, Majzner RG, Mackall CL.

Nat Biomed Eng. 2018 Jun;2(6):377-391. doi: 10.1038/s41551-018-0235-9. Epub 2018 Jun 11. Review.

PMID:
31011197
2.

Pharmacologic control of CAR-T cell function using dasatinib.

Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL.

Blood Adv. 2019 Mar 12;3(5):711-717. doi: 10.1182/bloodadvances.2018028720. No abstract available.

3.

Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.

Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL.

J Natl Cancer Inst. 2019 Jan 30. doi: 10.1093/jnci/djy209. [Epub ahead of print]

PMID:
30698726
4.

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL.

Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17.

PMID:
30655315
5.

CAR T cell therapy: inroads to response and resistance.

Brown CE, Mackall CL.

Nat Rev Immunol. 2019 Feb;19(2):73-74. doi: 10.1038/s41577-018-0119-y. No abstract available.

PMID:
30631206
6.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

7.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

8.

Tumor Antigen Escape from CAR T-cell Therapy.

Majzner RG, Mackall CL.

Cancer Discov. 2018 Oct;8(10):1219-1226. doi: 10.1158/2159-8290.CD-18-0442. Epub 2018 Aug 22. Review.

PMID:
30135176
9.

Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.

Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Struemph K, Kane E, Yates B, Delbrook C, Mackall CL, Lee DW, Fry TJ, Shah NN.

J Immunother. 2018 Sep;41(7):350-358. doi: 10.1097/CJI.0000000000000241.

PMID:
30048343
10.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL.

Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.

PMID:
29891538
11.

Fludarabine and neurotoxicity in engineered T-cell therapy.

Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G.

Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7.

PMID:
29789639
12.

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL.

Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16.

13.

Neurotoxicity Associated with a High-Affinity GD2 CAR-Letter.

Majzner RG, Weber EW, Lynn RC, Xu P, Mackall CL.

Cancer Immunol Res. 2018 Apr;6(4):494-495. doi: 10.1158/2326-6066.CIR-18-0089. No abstract available.

14.

Engineering a designer immunotherapy.

Mackall CL.

Science. 2018 Mar 2;359(6379):990-991. doi: 10.1126/science.aas9434. No abstract available.

PMID:
29496866
15.

Immunotherapy for acute lymphoblastic leukemia: from famine to feast.

Davis KL, Mackall CL.

Blood Adv. 2016 Dec 27;1(3):265-269. doi: 10.1182/bloodadvances.2016000034. eCollection 2016 Dec 27.

16.

CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity.

Mackall CL, Miklos DB.

Cancer Discov. 2017 Dec;7(12):1371-1373. doi: 10.1158/2159-8290.CD-17-1084.

17.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

18.

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM.

Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003.

19.

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL.

Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.

20.

Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.

Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, Vielh P, Daugaard M, Sorensen PH, Mackall CL, Maris JM.

Cancer. 2017 Oct 1;123(19):3807-3815. doi: 10.1002/cncr.30724. Epub 2017 Jun 13.

21.

Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.

Majzner RG, Heitzeneder S, Mackall CL.

Cancer Cell. 2017 Apr 10;31(4):476-485. doi: 10.1016/j.ccell.2017.03.002. Epub 2017 Mar 30. Review.

22.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.

Stroncek DF, Lee DW, Ren J, Sabatino M, Highfill S, Khuu H, Shah NN, Kaplan RN, Fry TJ, Mackall CL.

J Transl Med. 2017 Mar 16;15(1):59. doi: 10.1186/s12967-017-1160-5.

23.

Autologous lymphapheresis for the production of chimeric antigen receptor T cells.

Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, Lee DW, Mackall CL, Conry-Cantilena C.

Transfusion. 2017 May;57(5):1133-1141. doi: 10.1111/trf.14003. Epub 2017 Feb 24.

24.

Neuroblastoma.

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA.

Nat Rev Dis Primers. 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78. Review.

PMID:
27830764
25.

Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2149-2154. doi: 10.1016/j.bbmt.2016.08.028. Epub 2016 Sep 12.

26.

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.

Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas RJ, Mackall CL.

Cancer Immunol Res. 2016 Oct;4(10):869-880. Epub 2016 Aug 22.

27.

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ.

Nat Commun. 2016 Jul 27;7:12320. doi: 10.1038/ncomms12320.

28.

Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.

Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, Khuu H, Merchant MS, Mackall CL.

Cytotherapy. 2016 Jul;18(7):893-901. doi: 10.1016/j.jcyt.2016.04.003. Epub 2016 May 17.

29.

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR.

Cancer Genet. 2016 May;209(5):182-94. doi: 10.1016/j.cancergen.2016.03.004. Epub 2016 Apr 5. Review.

30.

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.

Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG.

Clin Cancer Res. 2016 Jul 15;22(14):3643-50. doi: 10.1158/1078-0432.CCR-15-2516. Epub 2016 Feb 9.

31.

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.

Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, Steinberg SM, Sabatino M, Stroncek DF, Venkatasan AM, Wood BJ, Wright M, Zhang H, Mackall CL.

Clin Cancer Res. 2016 Jul 1;22(13):3182-91. doi: 10.1158/1078-0432.CCR-15-2550. Epub 2016 Jan 28.

32.

Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

Giles AJ, Reid CM, Evans JD, Murgai M, Vicioso Y, Highfill SL, Kasai M, Vahdat L, Mackall CL, Lyden D, Wexler L, Kaplan RN.

Cancer Res. 2016 Mar 15;76(6):1335-47. doi: 10.1158/0008-5472.CAN-15-0204. Epub 2015 Dec 30.

33.

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL.

Clin Cancer Res. 2016 Mar 15;22(6):1364-70. doi: 10.1158/1078-0432.CCR-15-0491. Epub 2015 Nov 3.

34.

Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology.

Orentas RJ, Mackall CL.

Crit Rev Oncog. 2015;20(3-4):315-27. Review.

PMID:
26349422
35.

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL.

Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.

36.

Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL.

Cui Y, Onozawa M, Garber HR, Samsel L, Wang Z, McCoy JP, Burkett S, Wu X, Aplan PD, Mackall CL.

Blood. 2015 May 7;125(19):2958-67. doi: 10.1182/blood-2014-10-609271. Epub 2015 Mar 26.

37.

Going back to class I: MHC and immunotherapies for childhood cancer.

Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP.

Pediatr Blood Cancer. 2015 Apr;62(4):571-6. doi: 10.1002/pbc.25359. Epub 2014 Dec 18. Review.

38.

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL.

Blood. 2015 Jan 29;125(5):784-92. doi: 10.1182/blood-2014-07-592881. Epub 2014 Dec 1.

39.

Immune-based therapies for childhood cancer.

Mackall CL, Merchant MS, Fry TJ.

Nat Rev Clin Oncol. 2014 Dec;11(12):693-703. doi: 10.1038/nrclinonc.2014.177. Epub 2014 Oct 28. Review.

PMID:
25348789
40.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
41.

Current concepts in the diagnosis and management of cytokine release syndrome.

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL.

Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29. Erratum in: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text.

42.

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL.

Sci Transl Med. 2014 May 21;6(237):237ra67. doi: 10.1126/scitranslmed.3007974.

43.

Introduction to the series of reviews on "Antibody derivatives as new therapeutics for hematologic malignancies".

Mackall CL.

Blood. 2014 Apr 10;123(15):2283-4. doi: 10.1182/blood-2014-02-554873. Epub 2014 Feb 26. No abstract available.

44.

Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.

Prieto DA, Johann DJ Jr, Wei BR, Ye X, Chan KC, Nissley DV, Simpson RM, Citrin DE, Mackall CL, Linehan WM, Blonder J.

Biomark Med. 2014;8(2):269-86. doi: 10.2217/bmm.13.101.

45.

T-cell adoptive immunotherapy for acute lymphoblastic leukemia.

Fry TJ, Mackall CL.

Hematology Am Soc Hematol Educ Program. 2013;2013:348-53. doi: 10.1182/asheducation-2013.1.348. Review.

PMID:
24319203
46.

A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ.

J Immunother. 2013 Oct;36(8):400-11. doi: 10.1097/CJI.0b013e3182a80213.

47.

Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.

Brehm C, Huenecke S, Pfirrmann V, Rossig C, Mackall CL, Bollard CM, Gottschalk S, Schlegel PG, Klingebiel T, Bader P.

Pediatr Hematol Oncol. 2013 Aug;30(5):349-66. doi: 10.3109/08880018.2013.802106. Epub 2013 Jun 12.

PMID:
23758210
48.

Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.

Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, Mackall CL.

Blood. 2013 Aug 15;122(7):1105-13. doi: 10.1182/blood-2012-08-449413. Epub 2013 Jun 11.

49.

Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.

Lundström W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL.

Proc Natl Acad Sci U S A. 2013 May 7;110(19):E1761-70. doi: 10.1073/pnas.1222303110. Epub 2013 Apr 22.

50.

Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.

Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.

Front Oncol. 2012 Dec 17;2:194. doi: 10.3389/fonc.2012.00194. eCollection 2012.

Supplemental Content

Loading ...
Support Center